SEC Filing Summary: 180 Life Sciences Corp. (ATNF)
Business Context and Reporting Period
This Form 8-K was filed by 180 Life Sciences Corp. on January 5, 2023, reporting events occurring on January 4, 2023. The registrant is a Delaware corporation with principal executive offices in Palo Alto, California. The filing addresses the status of the company's common stock (trading symbol: ATNF) and warrants (trading symbol: ATNFW) on The NASDAQ Stock Market LLC.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material event reported is the resolution of a listing deficiency:
- Previous Status: On September 30, 2020, the company received notice from Nasdaq that its common stock failed to maintain the minimum bid price of $1.00 for 30 consecutive business days.
- Current Status: On January 4, 2023, Nasdaq notified the company that it has regained full compliance with the Minimum Bid Price Requirement (Listing Rule 5550(a)(2)).
- Compliance Criteria Met: The closing bid price of the common stock was at or above $1.00 per share for 10 consecutive business days.
- Outcome: The matter regarding the minimum bid price deficiency is now closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of new risks or contingencies beyond the resolution of the listing compliance issue. The company issued a press release on January 5, 2023, to publicly disclose the regained compliance.
Key Facts for Investor Verification
- Verify the current trading price of ATNF to ensure it remains above the $1.00 minimum bid price threshold to avoid future delisting notices.
- Confirm the company's ongoing compliance with other Nasdaq listing requirements, as this filing only addresses the minimum bid price rule.
- Review the attached press release (Exhibit 99.1) for any additional context regarding the stock price performance leading to compliance.